Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)

The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy. Research Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS (fewer PSA tests, biopsies and clinic visits)? Patients will be allocated in a 1.1 ratio

Trial Details

NCT ID
NCT06280781
Phase
NA
Sponsor
Imperial College London
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • MRI Scans
Locations (sample)
  • Ascot, Berkshire, United Kingdom|51.41082,-0.6748
  • Dartford, Kent, United Kingdom|51.44657,0.21423
  • Bradford, United Kingdom|53.79391,-1.75206
  • Chertsey, United Kingdom|51.38812,-0.50782
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Age 18 years or above (no upper limit)
  • Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all).
  • Diagnostic bi-parametric or multiparametric MRI
  • Diagnostic systematic biopsy +/- targeted biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →